Results from Phase 3 MonumenTAL-3 Study at EHA 2026: Talquetamab Plus Daratumumab Showed Significant Reduction in Risk of Disease Progression in Relapsed/Refractory Myeloma Read more about Results from Phase 3 MonumenTAL-3 Study at EHA 2026: Talquetamab Plus Daratumumab Showed Significant Reduction in Risk of Disease Progression in Relapsed/Refractory MyelomaAdd new comment
International Myeloma Foundation’s Black Swan Research Initiative Presents Data and Results of Phase 2 ASCENT Cure Trial at EHA 2026 Congress Read more about International Myeloma Foundation’s Black Swan Research Initiative Presents Data and Results of Phase 2 ASCENT Cure Trial at EHA 2026 Congress Add new comment
The Lancet Publishes Interim Analysis Data for the SUCCESSOR-2 Trial, Presented at 2026 ASCO and EHA Read more about The Lancet Publishes Interim Analysis Data for the SUCCESSOR-2 Trial, Presented at 2026 ASCO and EHA Add new comment
International Myeloma Foundation (IMF) and International Myeloma Working Group (IMWG) to Honor 2026 Kyle and Durie Achievement Awardees, Dr. Hermann Einsele and Dr. Noopur Raje Read more about International Myeloma Foundation (IMF) and International Myeloma Working Group (IMWG) to Honor 2026 Kyle and Durie Achievement Awardees, Dr. Hermann Einsele and Dr. Noopur RajeAdd new comment
EU Approves Subcutaneous Sarclisa (isatuximab): The First Myeloma Treatment via On-Body Injector Read more about EU Approves Subcutaneous Sarclisa (isatuximab): The First Myeloma Treatment via On-Body InjectorAdd new comment
May 2026 – Myeloma News from the Journals Read more about May 2026 – Myeloma News from the JournalsAdd new comment
We Are #MoreThanMyeloma on Capitol Hill Read more about We Are #MoreThanMyeloma on Capitol HillAdd new comment
2026 MAM Global Campaign Demonstrates the Spirit of #MoreThanMyeloma Read more about 2026 MAM Global Campaign Demonstrates the Spirit of #MoreThanMyeloma Add new comment
Phase 3 MagnetisMM-5 Trial Results: Elrexfio (elranatamab) Significantly and Clinically Improves Progression-Free Survival in RRMM Patients Who Received at Least One Prior Line of Treatment Read more about Phase 3 MagnetisMM-5 Trial Results: Elrexfio (elranatamab) Significantly and Clinically Improves Progression-Free Survival in RRMM Patients Who Received at Least One Prior Line of Treatment Add new comment
